HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Peptor Ltd.

Division of Evotec SE

Latest From Peptor Ltd.

Graffinity/MyoContract: Two Problems, One Solution

By merging with Swiss product development group MyoContract, Germany's Graffinity addresses its two key issues at once: a lack of products, and poor prospects for a viable listing in its home market. Europe's industry needs more such deals, but making them happen isn't easy.
BioPharmaceutical Business Strategies

European Financing: The Money's Back, But How Do You Get It?

Two of Europe's handful of IPOs this season are struggling to stay afloat. Bankruptcies continue among private German biotechs. Yet VCs have more money than ever and two of the European biotech flotations were the second- and third-largest globally during this window. What do Europe's biotechs need to do in this new, cautious and contradictory era in order to raise private funds and survive on the open markets? In Vivo Europe Rx asked three top leading European financiers.
BioPharmaceutical Europe

Recent Dealmaking (07/2004)

Summarizing the month in European dealmaking.

2004: Consolidation Year for European Biotech?

Despite investors' pleas, most observers agree there are still far too many small, sub-critical biotech firms in Europe. Yet two late-2003 deals-CeNeS' acquisition of TheraSci, and Develogen's merger with Peptor-may point to more consolidation both in public and private European biotech during 2004. And the early signs are that such deals may be driven less by sheer desperation, and more by a recognition of what both public and private investors want.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Evotec SE
  • Senior Management
  • Yoram Karmon, PhD, Chmn., Pres. & CEO
    Arie Reichmann, CFO
  • Contact Info
  • Peptor Ltd.
    Phone: (972) 8 940 1232
    Kiryat Weizman
    Rehovot, 76326